A COMPREHENSIVE REVIEW OF NIVOLUMAB AND IPILIMUMAB COMBINATION THERAPY IN ADVANCED MELANOMA

Melanoma is the most aggressive form of skin cancer and carries a poor prognosis in advanced stages. Until 2011, systemic treatments such as dacarbazine and high-dose interleukin-2 offered limited and short-lived survival benefits. The introduction of immune checkpoint inhibitors has revolutionized the management of metastatic melanoma. The mechanistic rationale for dual immune checkpoint blockade is discussed, highlighting complementary enhancement of antitumor T-cell activation and effector function. Clinical evidence from pivotal randomized trials, including CheckMate 067 and CheckMate 511, is critically appraised alongside real-world observational data. Combination therapy with nivolumab plus ipilimumab consistently demonstrates higher objective response rates and improved long-term survival compared with monotherapy, with durable responses extending beyond 10 years in selected patient subgroups. However, these benefits are accompanied by a substantially increased incidence of immune-related adverse events, necessitating careful patient selection, close monitoring, and proactive toxicity management. Emerging strategies, including modified dosing schedules and novel checkpoint combinations such as PD-1 plus LAG-3 blockade, aim to improve the benefit–risk balance. Overall, nivolumab plus ipilimumab represents a cornerstone first-line option for advanced melanoma, offering the potential for long-term disease control in a subset of patients, while ongoing research seeks to optimize safety and broaden durable responses. This review summarizes the global burden and epidemiology of melanoma, the evolution of systemic therapy from chemotherapy to immunotherapy, and the pharmacological profiles of Nivolumab (anti-PD-1) and Ipilimumab (anti-CTLA-4).